JPRN-UMIN000004103已完成未知
Investigation into Optimal Administration of Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid and Appropriate Timing of Arterial Phase of Enhanced Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma - Investigation into Optimal Administration of Ga-EOB-DTPA and Appropriate Timing of Arterial Phase of Enhanced Liver Magnetic Resonance Imaging for HCC
Department of Radiology, Graduate School of Medicine, University of Tokyo0 个研究点目标入组 150 人开始时间: 2010年8月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with lesions that are received prior RFA or TAE treatment. 2) Patients with a history of hypersensitivity to gadolinium-based contrast agent or this test drug. 3) Patients who have asthma. 4) Patients with severe kidney disease. (eGFR<30mL/min/1.73square meter or serum Cr>1.5mg/dl) 5) Patients during pregnancy or potential pregnancy. 6) Patients who are lactating women. 7) Patients who have advanced nyctophobia cabin.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate the safety, efficacy of gadopiclenol and how this drug is absorbed, distributed, metabolized, and eliminated from the body in children less than 2 years.Known or highly suspected abnormalities/ lesion(s) as detected by previous imaging examinations (including the fetal imaging) that need to be investigated by contrast-enhanced MRI of any body region including CNS.MedDRA version: 22.1Level: LLTClassification code 10029815Term: Nuclear magnetic resonance imagingSystem Organ Class: 10022891 - InvestigationsMedDRA version: 22.1Level: LLTClassification code 10058644Term: Nuclear magnetic resonance imaging whole bodySystem Organ Class: 10022891 - InvestigationsEUCTR2021-003825-31-PLGuerbet50
进行中（未招募）
1 期
Study to evaluate the safety, efficacy of gadopiclenol and how this drug is absorbed, distributed, metabolized, and eliminated from the body in children less than 2 years.Known or highly suspected abnormalities/ lesion(s) as detected by previous imaging examinations (including the fetal imaging) that need to be investigated by contrast-enhanced MRI of any body region including CNS.MedDRA version: 22.1Level: LLTClassification code 10029815Term: Nuclear magnetic resonance imagingSystem Organ Class: 100000004848MedDRA version: 22.1Level: LLTClassification code 10058644Term: Nuclear magnetic resonance imaging whole bodySystem Organ Class: 100000004848EUCTR2021-003825-31-HUGuerbet50
进行中（未招募）
1 期
Study to evaluate the safety, efficacy of gadopiclenol and how this drug is absorbed, distributed, metabolized, and eliminated from the body in children less than 2 years.Known or highly suspected abnormalities/ lesion(s) as detected by previous imaging examinations (including the fetal imaging) that need to be investigated by contrast-enhanced MRI of any body region including CNS.MedDRA version: 22.1Level: LLTClassification code 10029815Term: Nuclear magnetic resonance imagingSystem Organ Class: 100000004848MedDRA version: 22.1Level: LLTClassification code 10058644Term: Nuclear magnetic resonance imaging whole bodySystem Organ Class: 100000004848EUCTR2021-003825-31-BGGuerbet50
已完成
不适用
Investigation of suitable administration-time of GLP-1 receptor agonist on glycemic control in patients with type 2 diabetes: multicenter-randomized non-blind studyType 2 DiabetesJPRN-UMIN000004781Dokkyo Medical University Koshigaya Hospital Internal Medicine300
进行中（未招募）
1 期
Evaluation of Gadopiclenol for central nervous system magnetic resonance imagingPatient presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (e.g., primary and secondary tumors)MedDRA version: 20.1Level: LLTClassification code 10056941Term: MRI brainSystem Organ Class: 100000004848MedDRA version: 20.1Level: LLTClassification code 10056922Term: MRI brain abnormalSystem Organ Class: 100000004848EUCTR2018-003988-54-BEGuerbet250